Swiss Diabetes Venture Fund
VC Fund
Lausanne, Switzerland
Swiss Diabetes Venture Fund is a VC fund in Lausanne focused on Health Care and Medical Device. Swiss Diabetes Venture Fund is europe’s first venture fund dedicated to diabetes technology.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Swiss Diabetes Venture Fund invests in
Stages Swiss Diabetes Venture Fund invests in
Countries Swiss Diabetes Venture Fund invests in
Round sizes
Round size
- Series A
- $6.6M–$24M
Investment Focus
Industry
- Health Care 5 (100%)
- Medical Device 5 (100%)
- Medical 3 (60%)
- Therapeutics 1 (20%)
- Manufacturing 1 (20%)
Stage
- Series A 3 (60%)
- Venture - Series Unknown 2 (40%)
Country
- United States 2 (40%)
- Norway 1 (20%)
- Sweden 1 (20%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Luna Diabetes is a manufacturer of medical equipment. | $23.6M / Series A / Aug 18, 2025 | ||
| BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath. The company provides breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using it to diagnose and monitor chronicdiseases.It was founded in 2015 and headquartered in South San Francisco, California. | $7.6M / Venture - Series Unknown / Apr 05, 2024 | ||
| GlucoSet is medical device company that is developing sensor technology for improved glucose control in intensive care units.Blood glucose levels are elevated and unstable in hospital intensive care unit (ICU) patients. This leads to costly infections, increased length of stay and mortality. The GlucoSet intravascular sensor delivers continuousand accurate information on patient's blood glucose level, enabling normalization of glucose levels, without the risk of sudden and dangerously low glucose levels. | $6.6M / Series A / Jul 07, 2023 | ||
| There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need. | $7.9M / Series A / Jul 29, 2022 | ||
| Digital Diabetes Analytics radically fights diabetes with AI-based analysis of continuous glucose monitor (CGM) data. Despite rapid growth in CGM usage, impact on clinical outcomes is limited and healthcare professionals are overwhelmed by data. DDA in Sweden changes this with its AI-based decision support tool for patient prioritization andtreatment, turning data into improved outcomes and quality of life and reducing costs for healthcare providers. | Venture - Series Unknown / Jan 01, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Swiss Diabetes Venture Fund invest in?
Swiss Diabetes Venture Fund invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Swiss Diabetes Venture Fund's check size?
Swiss Diabetes Venture Fund typically joins rounds of $6.6M–$24M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Swiss Diabetes Venture Fund participates in.
When did Swiss Diabetes Venture Fund last invest?
The most recent investment recorded for Swiss Diabetes Venture Fund closed in Aug 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
